Should I Buy EVMN? EVMN 2026 Analysis

Should You Buy Evommune Inc (EVMN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

17.310

1 Day change

3.90%

52 Week Range

24.030

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.
Despite no proprietary buy signal today, EVMN looks like a good buy right now for an impatient investor because it’s trading below the pivot (~20.07) and closer to support, while Street views 2026 as catalyst-rich with large upside to targets ($35–$42).
Near-term momentum is not strong (bearish MACD), but the setup favors buying ahead of Phase 2 readouts rather than trying to time a perfect technical bottom.

Technical Analysis

Trend/Momentum: MACD histogram is negative (-0.0839) and expanding, signaling bearish/soft momentum in the near term.
RSI: RSI(6) at 46.8 (neutral) → not oversold; no clear rebound signal yet.
Moving averages: Converging MAs suggest consolidation/chop rather than a clean uptrend.
Key levels: Price ~18.94 is below pivot 20.07. Nearby support S1 ~17.84 (next S2 ~16.47). Resistance levels at R1 ~22.30 and R2 ~23.67.
Pattern-based forward bias (provided): ~-0.2% next day, +1.57% next week, +8.72% next month → mild short-term drift, better 1-month skew.

Positive Catalysts

- Multiple Phase 2 readouts in 2026 (EVO756 in CSU/CIndU and atopic dermatitis; EVO301 in AD) highlighted by multiple covering analysts.
- Analysts frame 2026 as a “catalyst-rich year” with “multiple ways to win,” increasing event-driven interest.
- Strategic/takeout angle: Oppenheimer notes potential acquisition attractiveness if data are positive (broad I&I applicability).
- Trading flows: Hedge funds/insiders neutral (no recent negative trend signal from these cohorts).

Neutral/Negative Catalysts

- Technical headwind: bearish MACD and price below pivot suggest the stock is not in a clean momentum uptrend right now.
- Event risk dependency: upside case is highly tied to upcoming clinical readouts (binary outcomes).
- No supportive near-term news flow in the past week to re-accelerate momentum.

Financial Performance

Financial snapshot unavailable (data error provided: "list index out of range"); cannot assess latest quarter financials or the latest quarter season from the supplied data.
As a clinical-stage biotech (implied by Phase 2 focus), valuation and near-term price action are likely driven more by clinical catalysts than by reported revenue/earnings trends.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent rating/target trend: multiple new initiations in Jan 2026 are uniformly bullish:
- Raymond James (2026-01-07): Strong Buy, PT $40.
- H.C. Wainwright (2026-01-06): Buy, PT $35.
- Oppenheimer (2026-01-22): Outperform, PT $42.
Wall Street pros: strong catalyst roadmap, high unmet need positioning (oral approach), favorable risk/reward into readouts, potential strategic interest.
Wall Street cons: thesis relies on clinical execution/readout outcomes; shares can soften into/after catalysts if sentiment fades.
Influential/political trading: No recent congress trading data available (last 90 days).

7 Analyst Rating

Wall Street analysts forecast EVMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVMN is 38.6 USD with a low forecast of 35 USD and a high forecast of 42 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 16.660

Low

Averages

38.6

High

Current: 16.660

Low

Averages

38.6

High

Oppenheimer

Outperform

initiated

$42

AI Analysis

2026-01-22

Reason

Oppenheimer

Price Target

$42

AI Analysis

2026-01-22

initiated

Outperform

Reason

Oppenheimer initiated coverage of Evommune with an Outperform rating and $42 price target. The firm sees an attractive setup heading into three Phase 2 readouts this year for EVO756 in chronic spontaneous urticaria, atopic dermatitis, and EVO301 in AD. Oppenheimer thinks positive Phase 2 results in CIndU should translate to CSU given their shared mast-cell-driven pathophysiology and believes oral EVO756 is well-positioned to address high unmet need in CSU/atopic dermatitis. The firm sees an attractive risk/reward ahead of value-driving catalysts, potentially sending shares up 50%-100% for each readout and making Evommune an attractive acquisition target given broad applicability across I&I.

Raymond James

Strong Buy

initiated

$40

2026-01-07

Reason

Raymond James

Price Target

$40

2026-01-07

initiated

Strong Buy

Reason

Raymond James initiated coverage of Evommune with a Strong Buy rating and $40 price target. The firm views 2026 as a "catalyst-rich year" for Evommune. The shares at current levels offer a "compelling" risk/reward portfolio with "multiple ways to win," the analyst tells investors in a research note. Raymond James believes the company's chronic spontaneous urticaria readout in the first half of 2026 will attract the greatest investor attention.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EVMN

Unlock Now

EVMN Should I Buy

EVMN Should I Buy

Should You Buy Evommune Inc (EVMN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch